Inclacumab

Drug Profile

Inclacumab

Alternative Names: DSM ACC2641; LC1004-002; R 1512; RG1512; RO 4905417

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genmab; Roche
  • Developer Roche
  • Class Anti-inflammatories; Anti-ischaemics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Myocardial infarction; Peripheral vascular disorders

Most Recent Events

  • 28 Jan 2015 Discontinued - Phase-I for Peripheral vascular disorders (Prevention, In volunteers) in Australia (IV)
  • 28 Jan 2015 Discontinued - Phase-II for Acute coronary syndromes in Canada (IV)
  • 28 Jan 2015 Discontinued - Phase-II for Acute coronary syndromes in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top